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Abstract
Background: The Src homology-2 domain protein B (Shb) is an adapter protein operating downstream of several
tyrosine kinase receptors and consequently Shb regulates various cellular responses. Absence of Shb was recently
shown to reduce hematopoietic stem cell proliferation through activation of focal adhesion kinase (FAK) and thus
we sought to investigate Shb’s role in the progression of leukemia.
Methods: Wild type and Shb knockout bone marrow cells were transformed with a retroviral BCR-ABL construct
and subsequently transplanted to wild type or Shb knockout recipients. Disease latency, bone marrow and
peripheral blood cell characteristics, cytokine expression, signaling characteristics and colony formation were
determined by flow cytometry, qPCR, western blotting and methylcellulose colony forming assays.
Results: It was observed that Shb knockout BCR-ABL-transformed bone marrow cells produced a disease with death
occurring at earlier time points compared with corresponding wild type controls due to elevated proliferation of
transformed bone marrow cells. Moreover, significantly elevated interleukin-6 and granulocyte colony-stimulation
factor mRNA levels were observed in Shb knockout c-Kit + leukemic bone marrow cells providing a plausible
explanation for the concurrent peripheral blood neutrophilia. Shb knockout leukemic bone marrow cells also
showed increased ability to form colonies in methylcellulose devoid of cytokines that was dependent on the
concomitantly observed increased activity of FAK. Transplanting BCR-ABL-transformed Shb knockout bone marrow
cells to Shb knockout recipients revealed decreased disease latency without neutrophilia, thus implicating the
importance of niche-derived cues for the increase of blood granulocytes.
Conclusions: Absence of Shb accelerates disease progression by exerting dual roles in BCR-ABL-induced leukemia:
increased cell expansion due to elevated FAK activity and neutrophilia in peripheral blood, the latter dependent on
the genetic background of the leukemic niche.
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Hematopoiesis is a life-long process supported by a finely
tuned network of proto-oncogenes and tumor suppressor
genes controlling the self-renewal and proliferation of
hematopoietic stem and progenitor cells (HSCs and
HPCs). Deregulation of any of these elements has the po-
tential to give rise to neoplasms [1]. Leukemic cells thus
show characteristics of upregulated signaling cascades
promoting self-renewal, increased cell cycle entry as well
as prevention of apoptosis [2,3].
Chronic myeloid leukemia (CML) is myeloproliferative
malignancy induced by the translocation between chro-
mosomes 9 and 22 leading to the fusion of the c-ABL gene
with the break point cluster region (BCR) gene [4]. The
resulting oncogene BCR–ABL is a constitutively active
tyrosine kinase with the ability to affect a broad range of
signaling pathways including Ras, phosphatidylinositol-3
kinase (PI-3 K), and Rac [5-8]. Hence, cells expressing
BCR-ABL display increased proliferative ability combined
with reduced apoptotic rates and abnormal migratory
characteristics [9-12]. BCR-ABL may, in addition, cause
other types of leukemia.
Intracellular signaling events are not the only factors con-
tributing to the progression of the disease. A common fea-
t u r eo fm o s tt y p e so ft u m o r si st h e i ra b i l i t yt oc h a n g et h e
microenvironment to promote neoplastic growth. The
tumor cells can either secrete tumor –promoting factors or
the surrounding stroma can be induced to generate condi-
tions favorable for expansion of leukemic cells [13,14].
CML bone marrow secretes increased levels of interleukin
-6 (IL -6) and granulocyte colony –stimulating factor (G –
CSF), both established as cytokines that stimulate myeloid
expansion and differentiation [10,11,15-17]. Additionally, in
leukemia, the stromal compartment has a reduced ability to
support normal hematopoiesis, thus further enhancing the
growth advantage of the leukemic cells [10,11,18,19].
The adaptor protein Shb is one of four members in a
family of adaptor proteins with homologous tyrosine phos-
phorylation sites and Src homology 2 (SH2) domains
[20-23]. Shb has been shown to operate downstream of
tyrosine kinase receptors exerting versatile effects on a
number of signaling pathways [24]. The SH2 domain of
Shb binds to phosphotyrosines on activated receptors such
as the platelet derived growth factor receptor (PDGFR),
the IL-2 receptor and the T cell receptor (TCR) [24].
Shb’s various signaling domains further recruit intracel-
lular signaling mediators, including focal adhesion
kinase (FAK), Src, phosphatidylinositol 3-kinase (PI3K),
Vav-1, and c-Abl [24,25], thereby regulating cytoskeletal
rearrangements, proliferation as well as apoptosis [24].
Shb’s influence on the hematopoietic system has been
documented in a number of studies. Shb knockout embry-
onic stem cells display reduced colony formation and de-
layed expression of hematopoietic markers [26]. CD4+ TH
cells isolated from a Shb knockout mouse exhibit a TH2
biased cytokine profile upon in vitro stimulation [27]. In
HSCs, the loss of Shb results in hyperactivation of FAK
leading to impaired HSC proliferation and failure to up-
hold long –term maintenance of the myeloid compart-
ment [28]. The reduction of HSC proliferation prompted
us to investigate Shb’s role in a stem cell mediated myelo-
proliferative model. BCR-ABL-induced myeloid disease is
one of the most established systems to study factors that
are known to be coordinated downstream of tyrosine kin-
ase signaling. We observe that Shb-deficiency results in a
more rapid progression of disease.
Results
Loss of Shb results in BCR-ABL-driven leukemogenesis
with shorter latency
A recent study suggested that Shb knockout HSCs are
less proliferative and fail to maintain the myeloid com-
partment over time [28] and consequently, we decided
to investigate the effect of Shb deletion on the develop-
ment of myeloid neoplasia. Shb knockout and wild type
bone marrow cells were transformed with BCR-ABL-
GFP encoding retrovirus and subsequently transplanted
to wild type recipients. As the mice were monitored for
disease progression Shb knockout recipients displayed
symptoms and became moribund at earlier time points
than their wild type counterparts (Figure 1a). In addition,
when comparing the average life-span of wild type and
Shb knockout transplanted mice in each individual experi-
ment (a separate event of parallel wild type and Shb
knockout bone marrow transfection followed by trans-
plantation to recipient mice of which mean survivals were
determined in each group) it was observed that absence of
Shb shortened survival by 2.7±0.4 days (n=5, p<0.01).
Upon gross pathological examination there were no differ-
ences between mice receiving wild type or Shb knockout
leukemic bone marrow at the time of death. Weight loss
is one of the more prominent symptoms at the end stage
of the disease; Shb null mice started losing weight earlier
but the end stage weight did not significantly differ be-
tween the two groups (Figure 1b). The number of cells
was also found to be equal in wild type and Shb knockout
bone marrows (Figure 1c) and flow cytometric analysis of
myeloid lineage markers Gr-1 and Mac-1 failed to demon-
strate any differences between wild type and Shb deficient
bone marrows in either GFP+(BCR-ABL-GFP)o rt o t a l
myeloid cell numbers (Figure 1d and e) [29]. As the
leukemia progresses, immature hematopoietic cells will be
driven out of the bone marrow and extramedullary
hematopoiesis will occur at alternative sites such as spleen
and liver. The result is considerable splenomegaly and
hepatomegaly. In addition, leukemic cells collect in
the lungs causing pulmonary hemorrhage [30]. End
stage spleen and liver weights were, however, found
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and Shb knockout bone marrows (Figure 1b) and
hematoxylin-eosine stained sections of spleens, livers and
lungs also did not reveal any differences with regards to
leukemic cell infiltration (Additional file 1: Figure S1). The
percentage GFP+myeloid cell number was decreased
slightly in Shb knockout spleen whereas the non-leukemic
myeloid cell percentage was unchanged (Additional file 1:
Figure S1). Analysis of May Grünwald-Giemsa stained
peripheral blood smears did on the other hand reveal
significantly increased numbers of leukocytes (Figure 2a
and c) in the absence of Shb. Normally, more aggressive
forms of myeloid leukemia are distinguished by elevated
levels of immature, blast cells in peripheral blood [30].
Shb deficiency did, however, confer increased proportions
of cells with a mature neutrophil morphology and reduced
relative numbers of blasts (Figure 2b and c). Although the
relative proportion of blast cells was lower in the Shb
knockout, absolute numbers of blast cells were not
different (105±11 × 10
6 cells per ml in the wild type
and 126± 22 × 10
6 cells per ml in the Shb knockout).
More mature stages of myeloid cells are defined as
Gr-1
HiMac-1
Hi [29]. However Gr-1 and Mac-1 expression
in peripheral blood did not differ significantly between
wild type and Shb knockout samples (Figure 2d and e).
Although the histological findings in peripheral blood
could not be corroborated by changes in expression levels
of lineage defining markers through FACS analysis, it is
plausible that, as these cells are neoplastic, cell sur-
face marker expression does not faithfully reflect mor-
phological maturity. Notably, when the Gr-1
HiMac-1
Hi
population was examined for expression of BCR-ABL,
determined by FACS analysis of GFP
+ cells, recipients of
Shb null transformed bone marrow displayed a decreased
percentage of BCR-ABL
+ myeloid cells in peripheral
blood. Shb deficient samples showed an almost 1:1
ratio of BCR-ABL
+ to BCR-ABL
− cells whereas wild
type recipients had a ratio of 1.8:1 (Figure 2d and f).
S i n c et h et o t a lb l o o dc e l lc o u n tw a sh i g h e ri nt h e
Shb knockout (Figure 2a), the absolute numbers of
BCR-ABL
+ myeloid cells did, however, not differ between
wild type and knockout, suggesting that the non-malignant
Figure 1 Effects of Shb deletion on disease progression in murine model of CML. (a) Kaplan-Meier curve demonstrating survival of mice
receiving either wild type or Shb knockout BCR-ABL transformed bone marrow from 5-FU treated mice. (b) Analysis of various disease parameters
including liver and spleen weight as well as weight loss at the end-stage of the disease. (c) Bone marrow cell numbers from the tibia, femur and
the iliac bones were determined at the time of death. (d and e) Bone marrow cells were stained with fluorescently labeled antibodies directed
against Gr-1 and Mac-1 and subsequently analyzed with FACS for GFP (BCR-ABL), Mac-1 and GR-1. Plots are representative of a typical experiment.
Data are presented as mean±SEM and based on 15 mice of each genotype from 5 independent experiments (retroviral transformation and
transplantation occurring at 5 separate occasions). *denotes p< 0.05 as determined by Student’s t-test.
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absence of Shb (Additional file 2: Figure S2).
In summary, the loss of Shb expression in malignant
hematopoiesis exhibits a disease with shorter latency.
Simultaneously, elevated numbers of mature neutrophil
granulocytes are observed in peripheral blood.
Shb deletion confers a proliferative advantage and
reduces apoptosis in BCR-ABL
+ lineage-negative cells
In order to further examine how the loss of Shb expression
accelerates BCR-ABL-induced leukemia, the proliferation
status of hematopoietic stem and progenitor cells was
determined at the time of death. Most of the bone
marrow’s stem and progenitor potential is found within the
Lin
−c-Kit
+ population of cells. Flow cytometric analysis
of the proliferation marker Ki-67 within the BCR-ABL
+
Lin
− c-Kit
+ population revealed a 1.9-fold increase in the
proliferation rate (Figure 3a upper panel and Figure 3b) in
Shb knockout bone marrow. Moreover, the more dif-
ferentiated Lin
+ c-Kit
+ population was also found to ex-
hibit an elevated cell cycle rate in Shb null bone marrow
(Figure 3a middle panel and Figure 3c). Absence of Shb did
n o ta f f e c tt h es i z e so ft h eL i n
−c-Kit
+CD150
+CD48
−,t h e
Figure 2 Evaluation of peripheral blood profile in leukemic wild type and Shb knockout mice. Peripheral blood smears were stained with
May Grünwald-Giemsa; (a and c) the white blood cell count was established by differential counts and (b and c) the proportions of morphologically
mature and immature cells were determined [stars point to blast cells and arrow to mature neutrophils]. (d and e) FACS analysis of Gr-1 and Mac-1
expression in peripheral blood. (d and f) The ratio of BCR-ABL
+ and BCR-ABL
− within the myeloid compartment was determined by evaluation of GFP
+
expression using FACS analysis. The plots are representative of a typical experiment. The results are presented as mean values±SEM from 9 mice of
each genotype in 3 independent experiments. ** and * represents p<0.01 and p<0.05 respectively as determined by Student’s t-test.
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−c-Kit
+ populations (Additional file 3:
Figure S3a, b and c).
A hallmark of BCR-ABL transformed bone marrow
cells is their resistance to apoptosis [9]. To deter-
mine if the apoptotic rate was also altered in the
absence of Shb, BCR-ABL
+ Lin
−c-Kit
+ bone marrow
cells were stained for cleaved caspase-3 when the
mice became moribund. A modest, but significant
decrease in the percentage of cleaved caspase-3
+
cells indicates that BCR-ABL
+ Lin
− c-Kit
+ cells are
less apoptotic as a result of Shb deletion (Figure 3a
lower panel and Figure 3d). There was no effect on
apoptosis in the Lin
+ c-Kit
+ population (data not
shown). In conclusion, the data imply that ablation
of Shb expression is associated with an increased
expansion of the leukemic lineage-negative progenitor
cell population through enhancement of proliferation
and survival.
Shb knockout leukemic bone marrow is hypersensitive to
cytokine stimulation and expresses increased levels of
G-CSF and IL-6
Normal bone marrow only forms hematopoietic colonies
in the presence of the appropriate cytokines; malignantly
transformed stem and progenitor cells however, are
capable of growth factor independent proliferation and
differentiation [31]. To assess the response to cytokine
stimulation, cells from leukemic wild type and Shb
knockout bone marrows were seeded into semisolid
media containing a cytokine cocktail with the potential
to support myeloid as well as erythroid differentiation.
Both wild type and Shb null bone marrow readily
formed colonies with no significant difference in the
number or the types of colonies formed (Figure 4a).
When plating the cells on a gradient of granulocyte-
monocyte colony-stimulating factor (GM-CSF), noticeable
differences were observed as compared to the experiments
Figure 3 Proliferation and apoptosis in BCR-ABL
+ hematopoietic progenitors assessed by flow cytometric analysis of Ki-67 and cleaved
Caspase-3. (a, b and c) The cell cycle status in BCR-ABL
+Lin
−c-Kit
+ and BCR-ABL
+Lin
+ bone marrow was examined by staining for proliferation
marker Ki-67 in combination with the DNA binding dye Hoechst 33342. FACS plots are representative of an average experiment. (a and d) The
staining for presence of cleaved Caspase-3 was used to determine the percentage of apoptotic cells within the BCR-ABL
+Lin
−c-Kit
+ population.
FACS plots are representative of a typical experiment. Data are presented as mean values±SEM with 9 mice from each genotype from 3
independent experiments. *denotes p<0.05 as determined by Student’s t-test.
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mented with multiple cytokines. It was revealed that Shb
deficient bone marrow had an increased potential to sup-
port cytokine-independent growth and responded at lower
concentrations of GM-CSF. In the absence of cytokines
Shb knockout bone marrow formed 3 times as many col-
onies as the wild type (Figure 4b) and at a concentration
of 0.1 ng/ml GM-CSF the knockout produced twice as
many colonies.
To further explore the cytokine signaling networks in
our model, the expression levels of a number of cytokines,
known to regulate BCR-ABL-induced leukemogenesis and
hematopoietic cell proliferation and differentiation, were
determined. In order to facilitate a distinction between
cytokine production within the bone marrow as a whole
and the hematopoietic compartment, bone marrow was
first fractionated based on c-Kit expression, as most HSCs
and HPCs are c-Kit
+. Transcription of GM-CSF was
unchanged in both the c-Kit
+ compartment and in unfrac-
tionated bone marrow (Figure 4c and Additional file 4:
Figure S4). The expression of G-CSF and IL-6 was on the
other hand significantly elevated in c-Kit
+ cells (Figure 4c)
but not in total bone marrow (Additional file 4: Figure S4),
suggesting that the increased cytokine production is
limited to the hematopoietic compartment. This is in
line with previous reports suggesting that leukemic
progenitors secrete IL-6 and G-CSF in an autocrine
fashion [10,32]. Other factors, such as TNFα,I L - 1 α,
IL-1β, IL-4, MIP-1α,M I P - 1 β, SCF, IL-3, thrombopoietin
and angiopoietin-2, have also been demonstrated to be
important factors in promoting the proliferation of
leukemic HSCs and HPCs [10,18]. The transcript levels of
these factors were therefore determined in c-Kit enriched
and unfractionated bone marrow, but no differences were
detected between wild type and Shb deficient samples
(Additional file 4: Figure S4).
Additionally, G-CSF has been linked to impaired bone
marrow retention of leukemic HSCs due to decreased
production of the chemokine CXCL12 by bone marrow
stromal cells [10]. There was however no detectable differ-
ence in CXCL12 expression in total (unfractionated) bone
marrow (relative expression of CXCL12 was 1 ± 0.15
in wild type and 0.73±0.25 in Shb knockout). Re-
duced expression of CXCL12 in bone marrow has
been shown to increase the number of HSCs found
in the spleen [10]. Flow cytometric analysis of splenic
HSCs revealed no difference between wild type and Shb
knockout recipients (data not shown), further supporting
the notion that the elevated levels of G-CSF do not appear
to affect the invasion of Shb deficient leukemic HSCs to
the spleen.
These results thereby indicate that Shb serves as a
modulator of cytokine expression levels thus possibly
explaining the increased numbers of neutrophils in
Figure 4 Effects of Shb deficiency on hematopoietic colony
formation ability and cytokine expression in BCR-ABL-
transformed bone marrow. (a) Bone marrow cells were plated on
M3434 semisolid medium containing cytokines supportive of
myeloid and erythroid colony growth. The number and types of
colonies were determined on day 10 of culture [Granulocyte
Erythroid Monocyte Megakaryocyte (GEMM), Burst-forming Unit
Erythroid (BFU-E), Granulocyte Monocyte (GM), Monocyte (M),
Granulocyte (G)]. Data are means based on 3 mice of each genotype.
(b) A gradient of 0, 0.1 and 1 ng/ml of GM-CSF was used to evaluate
cytokine responsiveness in leukemic bone marrow cells. Results are
presented as percentage of the highest GM-CSF dose. Means±SEM
are representative of 3 mice of each genotype. (c) The expression
levels of various hematopoietic cytokines were determined by
semi-quantitative real-time RT-PCR in samples isolated from c-Kit
+
leukemic bone marrow. All Ct values were normalized to β-actin and
Shb knockout samples were related to corresponding wild type values.
Means are presented as 2
-ΔC
t ±SEM to demonstrate fold change in
mRNA content. Data are based on 6 mice of each
genotype from 2 independent experiments for c-Kit
+ cells and 3 mice
of each genotype from 1 experiment for unfractioned bone marrow.
*denotes p<0.05 respectively as determined by Student’s t-test.
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marrow.
Accelerated BCR-ABL-induced leukemia in Shb knockout
recipient mice as a consequence of Shb deficiency
We decided to investigate the progression of disease when
BCR-ABL-transformed wild type and Shb knockout bone
marrow cells were transplanted to Shb knockout recipient
mice instead. The myeloproliferative leukemia was also ac-
celerated in this setting when compared to wild type con-
trol (Figure 5a). Transplantation of BCR-ABL-transfected
bone marrow to wild type and knockout recipients in a
parallel experiment revealed no consistent difference in la-
tency (results not shown). Unlike the situation with wild
type recipients (see Figure 2b and c), no signs of neu-
trophilia were observed (Figure 5b and c) when Shb
knockout bone marrow was transplanted to knockout
recipients. Colony formation in methylcellulose supple-
mented with cytokines was similar regardless of bone
marrow cell genotype (Figure 5d). The expression of G-
CSF and IL-6 in c-Kit
+ bone marrow cells was un-
altered by Shb deficiency (Figure 5e), explaining the ab-
sence of peripheral blood neutrophilia. This contrasted
to what was seen with wild type recipients, suggesting
that the host genotype in combination with the geno-
type of the transformed donor cells is critical for this
response. The most likely explanation is interplay be-
tween transformed bone marrow cells and leukemic
niche cells. Consequently, increased production of G-
CSF and IL-6 in BCR-ABL Shb knockout bone marrow
cells required a wild type niche.
Enhanced FAK and STAT3 activity of Shb deficient
leukemic c-Kit
+ bone marrow cells
An increase in basal signaling activity in response to ab-
lated Shb expression has been noted in several types of
tissue [27,28]. The activities of pathways controlling pro-
liferation and survival were therefore analyzed in un-
stimulated c-Kit
+ bone marrow cells. As noted in non-
malignant HSCs [28], FAK activity was also increased in
leukemic Shb knockout c-Kit
+ bone marrow (Figure 6a)
transplanted to wild type mice. Myeloid leukemias are
often characterized by hyperphosphorylation of STAT3
and STAT5 [33]. STAT5 phosphorylation was similar in
Shb knockout and wild type samples (Additional file 5:
Figure S5), whereas STAT3 activity was significantly
increased in the knockout (Figure 6b). Notably, both
Figure 5 Effects of Shb deletion on disease progression of BCR-ABL-transformed bone marrow cells transplanted to Shb knockout
recipient mice. (a) Kaplan-Meier curve demonstrating survival of Shb knockout mice receiving either wild type or Shb knockout BCR-ABL-transformed
bone marrow. (b) White blood cell counts in peripheral blood at the time of death. (c) Relative numbers of mature neutrophils and blasts in peripheral
blood at the time of death. (d) Colony formation assay of c-Kit enriched bone marrow cells grown in cytokine-supplemented methylcellulose.
(e) Cytokine mRNA levels in c-kit-enriched bone marrow cells.
Gustafsson et al. Journal of Hematology & Oncology 2014, 7:45 Page 7 of 13
http://www.jhoonline.org/content/7/1/45G-CSF and IL-6 signal via STAT3 activation [34,35].
When FAK and STAT3 activities were monitored in
leukemic Shb deficient c-Kit
+ bone marrow isolated
from Shb knockout recipient mice, increased activity of
FAK was detected (Figure 6c) whereas STAT3 activity was
not consistently elevated (Figure 6d). Consequently, FAK
activation is a consistent feature of BCR-ABL-transformed
Shb knockout bone marrow cells. STAT3 activity, on the
other hand reflects the local cytokine milieu, which in turn
depends on the interactions between the niche and the
transformed bone marrow cells.
Elevated FAK activity is important for the proliferative
ability of BCR-ABL-transformed Shb knockout bone mar-
row cells
To address the relevance of the elevated FAK activity, c-
Kit
+ leukemic bone marrow cells were isolated and cul-
tured in methylcellulose without cytokine addition (i.e. ab-
sence of GM-CSF) in the absence (control) or presence of
FAK inhibitor 14. Shb knockout bone marrow cell colony
formation was increased compared with corresponding
wild type controls regardless of whether the cells were
isolated from wild type or Shb knockout recipient mice
(Figure 7a and c). The FAK inhibitor caused a statistically
significant reduction in the numbers of colonies formed
by the Shb knockout bone marrow cells (Figure 7a and c).
Dividing the number of colonies without FAK inhibitor
treatment by that with FAK inhibitor treatment in the wild
type situation yielded a ratio as high or even higher than
the corresponding knockout situation, suggesting the pos-
sibility that there is indeed an effect of the FAK inhibitor
on wild type leukemic bone marrow colony formation as
well. However, the total number of colonies was too small
relative the errors to obtain a statistical significant differ-
ence. We also determined the inhibitor-induced reduction
in colony formation after FAK inhibition (Figure 7b and d)
to illustrate the effect in the Shb knockout situation. This
was significantly larger than that observed in wild type
bone marrow cells (Figure 7b and d) suggesting a prefer-
entially greater importance of FAK signaling for prolifera-
tion in transformed Shb knockout bone marrow cells.
Assuming that the total number of colonies formed
reflects the proliferative status of the bone marrows at the
time of death, the data thus support the view that elevated
FAK activity as a consequence of Shb deficiency causes
increased cell expansion accelerating the progression of
disease. It is also possible that FAK plays a role for wild
type leukemic cell colony formation as well.
Discussion
The adaptor protein Shb has been implicated in intracel-
lular signaling events regulating proliferation, apoptosis
and differentiation in a number of different cell types.
Recently, HSC exhibited less proliferative activity in Shb
knockout mice due to alterations in FAK signaling [28].
The present study aimed at relating those observations
to conditions of neoplastic hematopoiesis. The results
suggest that Shb depletion accelerates BCR-ABL-driven
progression of myeloid neoplasia by causing decreased
latency and increased numbers of myeloid cells in periph-
eral blood due to elevated FAK activity. In addition, niche-
dependent cues have an impact on disease progression
with a bearing on cytokine production in bone marrow
cells and neutrophilia in peripheral blood.
Figure 6 Activity of FAK (a, c) and STAT3 (b, d) in c-Kit
+ bone marrow cells from leukemic mice. The phosphorylation status of FAK and
STAT3 was determined by Western blot analysis. (a and b) show bone marrow cells from wild-type recipients, (c and d) show bone marrow cells
from Shb knockout recipients. Activation was evaluated by immunoblotting for phospho- and total FAK and STAT3 respectively. Protein phosphorylation
was related to total protein content on the same blot and signal strength was estimated by densitometric analysis. Means are presented in arbitrary units
±SEM and are based on 6 mice of each genotype in 2 independent experiments. * denotes p <0.05 respectively as determined by Student’s t-test.
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creased in normal HSCs in Shb deficient mice [28]. A
similar increase in FAK activity was observed in BCR-
ABL-transformed Shb knockout c-Kit
+ bone marrow. Our
current knowledge of FAK’s effects on leukemogenesis is
limited although the bulk of data suggest that active FAK
promotes leukemogenesis. BCR-ABL appears to induce
FAK phosphorylation and siRNA silencing of FAK reduces
survival of AML leukemia cell lines [36,37]. Additionally,
observations from murine models and AML patients sug-
gest that FAK may influence leukemia progression [38,39].
FAK is mainly activated by integrins, thus mediating sig-
nals between cells and their respective surroundings.
Leukemic cells enhance their own growth by altering the
bone marrow microenvironment [10,11,18]. FAK signaling
could provide a key link between leukemic cells and the
stromal cells of the hematopoietic niche. FAK expressing
AML cells have been demonstrated to enhance the ability
of bone marrow stroma to support leukemic growth
through direct contact [40]. Moreover, in a recent study
utilizing a murine model of BCR-ABL-induced leukemia,
it was shown that soluble factors synergize with an un-
identified contact-dependent mechanism to drastically
change the hematopoietic niche composition to promote
neoplastic progression [18]. The present colony formation
experiments adding a FAK inhibitor in the absence of cy-
tokines lend strong support to the notion that the in-
creased tumor burden of transformed Shb knockout bone
marrow cells is mainly due to elevated FAK activity. In
Shb deficient BCR-ABL-transformed bone marrow, imma-
ture lin
−c-Kit
+ HSCs and HPCs as well as more differenti-
ated Lin
+ c-Kit
+ cells, were found to proliferate at an
increased rate and this finding is likely to reflect the same
mechanism as the colony formation assay.
The Shb deficient myelodysplastic neoplasia phenotype
is also intriguing as the rapid progression of disease is as-
sociated with a pronounced neutrophilia when studied in
wild type recipient mice. In most cases, more aggressive
forms of leukemia are distinguished by a blood profile
dominated by immature blasts [30]. Shb deficient c-Kit
+
leukemic bone marrow cells were on the other hand found
to express increased levels of granulopoietic factors IL-6
and G-CSF in these experiments. Myeloid differentiation
is supported by IL-6 through cell cycle regulation of mye-
loid progenitors and IL-6 also blocks lymphoid lineage
commitment thus further enhancing myeloid expansion
[16,41,42]. Moreover, leukemia progression is significantly
hampered in IL-6 knockout mice directly linking this cyto-
kine to disease [11]. This may involve effects on both ma-
lignant and non-malignant cells [11]. Peripheral blood
from recipients transplanted with transformed Shb knock-
out cells contained elevated numbers of BCR-ABL
− mye-
loid cells indicative of an expansion of non-malignant
cells, possibly a result of the increased IL-6 expression.
Neutrophil differentiation under homeostatic and stress
conditions depends on G-CSF providing survival and
Figure 7 Effect of FAK inhibition on colony formation of wild-type and Shb knockout BCR-ABL-transformed bone marrow cells.
c-Kit-enriched bone marrow cell (10
4) were plated in methylcellulose in the absence of cytokines in the absence or presence of 10 μM FAK
inhibitor 14 and cultured for 5 days after which colony numbers were determined. (a) Colony formation of bone marrow cells isolated from
wild-type recipients. (b) Inhibition of colony formation by inhibitor on bone marrow cells isolated from wild-type recipients. (c) Colony formation
of bone marrow cells isolated from Shb knockout recipients. (d) Inhibition of colony formation by inhibitor on bone marrow cells isolated from
Shb knockout recipients. The values in (b) and (d) were obtained by subtracting the inhibitor values from the corresponding control values.
Means±SEM for 6 dishes (three mice) each group are given. * and ** indicate p<0.05 and 0.01, respectively with one way ANOVA (Bonferroni).
# indicates p< 0.05 when compared with wild-type using a Students’ t-test. Ns=not statistically significant.
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Further demonstrating G-CSF’s effect on neutrophil ex-
pansion is the finding that chronic neutrophilic leukemia,
a rare myeloproliferative disorder characterized by exces-
sive expansion of the neutrophilic population in blood and
bone marrow, is linked to activating mutations in the
CSF3R gene, the human receptor for G-CSF [43].
STAT3 phosphorylation was significantly augmented
in c-Kit
+ bone marrow cells isolated from Shb knockout
recipients on wild type background. Notably, G-CSF and
IL-6 signaling pathways converge in the activation of the
transcription factor STAT3 and STAT3 is the main me-
diator of the proliferation and survival signals provided
by G-CSF and IL-6 [34,35,44,45]. The hyperphosphoryla-
tion displayed by Shb null cells is thus probably a result
of the increased production of G-CSF and IL-6.
Conclusions
The data presented suggest that Shb regulates cues in neo-
plastic bone marrow of importance for leukemic progres-
sion and that absence of Shb decreases disease latency.
The Shb-dependent effects include bone marrow cell in-
trinsic pathways (FAK) as well as niche-dependent signals
(cytokine production). Both of these components are
considered as druggable targets. Further exploration of
the effects of Shb deletion in hematopoietic malignancies
is therefore of importance to increase our understanding
of mechanisms that control leukemogenesis.
Methods
Mice
The generation of Shb knockout mice has been described
previously [46]. The Shb knockout genotype is not viable
on the C57Bl/6 background and the animals were there-
fore maintained on the Balb/c strain. The local animal
ethics committee at Uppsala University approved all
experiments.
Bone marrow transduction and transplantation assay
The pMIG-p210bcr/abl vector was used to produce retro-
viruses directing the expression of BCR-ABL-GFP as de-
scribed previously [47]. Balb/c Shb wild type or knockout
mice 8-10 weeks old were treated with 5 –fluorouracil (5-
FU) (Sigma-Aldrich, St. Lois, MO) at a dose of 150 mg/kg
body weight 6 days prior to bone marrow isolation, in
order to enrich for HSCs. Isolated donor bone marrow
was stimulated in RPMI 1640 (Sigma Aldrich) supple-
mented with 10% FCS (Sigma Aldrich), 2 mM L-glutam-
ine, streptomycin (0.1 mg/ml), penicillin (100 U/ml) (All
from Gibco, Paisley, UK), IL-3 (10 ng/ml), stem cell factor
(SCF) (10 ng/ml) and IL-6 (10 ng/ml) (all cytokines were
purchased from PeproTech, Rocky Hill, NJ) for 24 hours.
The cells were subsequently subjected to two rounds of
spin infections over the following 48 hours as described
previously [48]. Briefly, 8 × 10
6 cells were centrifuged for
90 minutes at 1000g and 30°C in medium containing the
aforementioned supplements as well as 25% viral super-
natant, 7.5 mM Hepes (Gibco) and 8 μg/ml Polybrene
(Millipore, Watford, UK). Infection efficiency was deter-
mined following the second spin inoculation and just prior
to transplantation by flow cytometric analysis of green
fluorescent protein (GFP) expression on a FACSCalibur
(BD Bioscience, Erembodegem, Belgium) and no differ-
ences were found between wild type and Shb knockout
bone marrow (5.6±1.0% in wt; 4.9±1.1% in knockout).
Recipient wild type or Shb knockout mice were irradiated
with two doses of 4.5 Gy separated by at least 2 hours in a
Nordion Gammacell 40 Exacto
137Cs irradiator (MDS
Nordion, Ottawa, ON). Immediately following the second
irradiation the recipients were retroorbitally injected with
ad o s eo f0 . 4– 1×1 0
6 cells (equal number of wild type
and Shb knockout cells was given per recipient mouse in
each experiment, i.e. transfection/transplantation event).
Pathological examination of diseased mice
T h em i c ew e r em o n i t o r e dd a i l yf r o md a y6p o s t–trans-
plantation for signs of disease such as a weight loss of more
than 15% of initial body weight, lethargy and splenomegaly.
Moribund mice were then sacrificed. Blood was collected
immediately prior to sacrifice and samples were prepared
for blood smears. Spleens, livers, and lungs were fixed in
4% buffered formalin and embedded in paraffin for later
histopathological analysis. Iliac bones, femurs and tibias
were dissected and bone marrow was collected. Bone mar-
row cells were extracted from the bones and used for fur-
ther downstream applications. Single cell suspensions of
spleen and bone marrow were also fixed in 4% paraformal-
dehyde to enable FACS analysis at a later time point.
Histology
Fixed and paraffin embedded organs were sectioned in
5 μm sections, mounted on microscope slides (Menzel
Gläser, Braunschweig, Germany) and stained with
Hematoxylin –Eosin. For differential blood counts, per-
ipheral blood smears were stained with May –Grünwald
Giemsa.
Fluorescent activated cell-sorting (FACS) analysis
Paraformaldehyde fixed peripheral blood and bone mar-
row single cell suspensions were stained with antibodies
directed against Gr -1-PE (eBioscience, Hartfield, UK)
and rat anti mouse Mac-1 (Invitrogen, Carlsbad, CA)
followed by incubation with goat anti-rat PE-Cy5.5 (Invi-
trogen) secondary antibody.
In order to identify the HSC population, bone marrow
and spleen cells were stained with a lineage excluding
cocktail consisting of rat anti-mouse antibodies CD3, CD8,
CD4, B220, CD19, Gr-1, and Mac-1. The samples were
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by staining with CD150-PE-Cy7 (BioLegend, San Diego,
CA), c-Kit-APC eFluor 780, and CD48-PE (eBioscience).
Proliferative and apoptotic rates were determined by
analysis of Ki-67 and cleaved Caspase-3. Paraformalde-
hyde fixed bone marrow was stained for lineage defining
markers and c-Kit as described above. This was followed
by permeabilization with BD Cytoperm Buffer (BD
Bioscience) and incubation with either Ki-67-PE antibody
(BD Bioscience) or cleaved Caspase-3 antibody (Cell
Signaling Technology, Beverly, MA). Cleaved Caspase-3
activity was detected by a PE-conjugated donkey anti-
rabbit antibody (eBioscience).
All flow cytometric experiments were analyzed with a
LSR II (BD Bioscience) and the data was analyzed with
FlowJo (TreeStar, Ashland, OR).
Colony forming assays
Freshly isolated bone marrow and spleen cells were plated
on methylcellulose medium M3434 (Stem Cell Technolo-
gies, Vancouver, BC) at seeding densities of 2 × 10
4 and 1 ×
10
5 cells, respectively. Bone marrow cells were also seeded
onto M3231 supplemented with a gradient of GM-CSF
(PeproTech) at concentrations of 0, 0.1 and 1 ng/ml or
10 μM FAK inhibitor 14 (Tocris Bioscience, Bristol, UK).
Colonies were scored at day 10.
RNA isolation and real-time reverse transcription PCR
In order to enrich bone marrow for hematopoietic stem
and progenitor cells, c-Kit
+ cells were isolated by magnetic
separation with anti-c-Kit labeled magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany), following
the instructions provided by the manufacturer. The num-
ber of c-Kit
+ cells was determined and RNA was subse-
quently isolated using a RNAeasy mini kit (Qiagen, Solna,
Sweden). Analysis of gene expression was performed with
one- step real-time reverse transcription PCR using Quan-
tiTect™ SYBR® Green RT-PCR kit (Qiagen). The following
PCR conditions were used; reverse transcription at 50°C
for 20 minutes, inactivation at 95°C for 15 minutes, 50 cy-
cles of denaturation at 94°C for 15 s, annealing for 25 s at
60°C, and extension at 72°C for 15 s. All primer sequences
can be provided upon request. The PCR reactions were all
run a LightCycler™ real- time PCR machine (Roche Diag-
nostics, Basel, Switzerland). The Cycle threshold (CT)
values were estimated with the LightCycler Software v 4.1
and transcript levels were normalized by subtracting the
corresponding β –actin values. Control was set at one dif-
ferences and presented as 2
-ΔKOCt-WTCt.
Immunoblotting
Bone marrow samples were enriched for c-Kit
+ cells as de-
scribed above. Promptly after isolation cells were allowed
to rest for 1 hour at 37°C in RPMI 1640 medium
supplemented with 10% serum. The cells were subse-
quently lyzed in SDS sample buffer (250 mM Tris-HCl
pH 6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue,
2% β-mercaptoethanol). Samples were then separated by
SDS-PAGE and transferred to a Hybond-P membrane
(GE Healthcare, Uppsala, Sweden). Blocking of the mem-
branes were done over night at 4°C in 5% BSA, followed by
probing for phospho-STAT3, STAT3, FAK (all from Cell
Signaling Technology), and phospho-FAK (Invitrogen).
Statistical analysis
All values are presented as mean±SEM. Comparisons of
two groups were analyzed by an unpaired Student t-test as
all data sets were found to be normally distributed. For
comparisons between multiple groups one-way ANOVA
was used, followed by post hoc analysis with Bonferroni’s
test. Statistical significance was set to p<0.05.
Additional files
Additional file 1: Figure S1. A) Hematoxylin-eosin stained sections of
l u n g ,l i v e ra n ds p l e e no fd i s e a s e dm i c et r a n s p l a n t e dw i t hBCR-ABL transformed
bone marrow cells of wild type or Shb knockout background to wild type
recipients. B) Percentage myeloid GFP+and GFP- cells in spleen. Means± SEM
are given and *indicates p< 0.05.
Additional file 2: Figure S2. Absolute numbers of BCR-ABL
+GFP
+ and
BCR-ABL
−GFP
− myeloid cells in peripheral blood. GFP
+ GR-1
Hi Mac-1
Hi and
GFP
− GR-1
Hi Mac-1
Hi cells were identified with FACS analysis in order to
estimate the number of BCR-ABL carrying cells. Means are presented in
arbitrary units± SEM and are based on 6 mice of each genotype in 2
independent experiments. *denotes p< 0.05 as determined by Student’s
t-test.
Additional file 3: Figure S3. Estimation of HSC proportions in murine
BCR-ABL transformed bone marrow. The proportions of HSCs were
established using FACS based on expression of lineage defining markers,
c-Kit, CD48 and CD150 (a). Right panels are Shb knockout. (b) Percentage
CD150+/CD48- cells among c-Kit+/Lin- cells and fraction of GFP+ cells
among the CD150+/CD48- cells. Means± SEM for 6 experiments are
shown. (c) Percentage lineage-/c-Kit + or lineage+/c-Kit +cells in bone
marrows of wild type or Shb knockout BCR-ABL transformed bone marrow
cells transplanted to wild type recipients. Means±SEM for 6 mice of each
genotype are given.
Additional file 4: Figure S4. Evaluation of cytokine expression in c-Kit
enriched and unfractionated (total) bone marrow. (a) Transcript levels of
SCF, IL-3, thrombopoietin (Thpo) and angiopoietin-2 (Angpt2) were
evaluated with semi-quantitative real-time RT-PCR using mRNA isolated
from c-Kit + leukemic bone marrow samples. The expression of
proinflammatory cytokines TNFα, IL-1α, IL-1β, IL-4, MIP-1α and MIP-1β
were determined in c-Kit
+ (b) and total bone marrow (d). Expression of
G-CSF, IL-6, SCF, IL-3, Angpt-2 and GM-CSF were determined in total
bone marrow (c). All Ct values were normalized to β-actin and Shb
knockout samples were related to corresponding wild type values. Means
are presented as 2
-ΔC
t ± SEM to demonstrate fold change in mRNA
content. Data are based on 6 mice of each genotype from 2 independent
experiments for c-Kit
+ cells and 3 mice of each genotype from 1 experiment
for unfractionated bone marrow.
Additional file 5: Figure S5. STAT5 activity in c-Kit
+ bone marrow from
leukemic mice. The activation of STAT5 was determined by Western blot
analysis of tyrosine phosphorylation by immunoblotting for phospho- and
total STAT5 respectively. Protein phosphorylation was related to total protein
content on the same blot and signal strength was estimated by densitometric
analysis. Means are presented in arbitrary units±SEM and are based on 6 mice
of each genotype in 2 independent experiments.
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